<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827747</url>
  </required_header>
  <id_info>
    <org_study_id>20150646</org_study_id>
    <nct_id>NCT02827747</nct_id>
  </id_info>
  <brief_title>The Role of Antioxidant Supplementation in Keratoconus Patients</brief_title>
  <official_title>The Role of Antioxidants in Keratoconus Patients—A Randomized Controlled Trial of Oral Supplementation of Glutathione, Vitamin A, Vitamin C and Vitamin E</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fight for Sight</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Keratoconus is the most common primary cornea ectasia, where the cornea undergoes structural
      changes, leading to loss of tissue integrity and vision loss. The prevalence of Keratoconus
      is 1:2000 in the general population. Oxidative stress has been thought to have a major effect
      in the disease pathogenesis of Keratoconus. In vitro studies have shown increase in
      metabolites related to oxidative stress in Keratoconus disease, and that Keratoconus cells
      undergo increased oxidative stress and tissue damage. Animal models have shown a therapeutic
      effect of Vitamin C (ascorbate) in corneal wound healing. Glutathione and Vitamins A, C, and
      E are important antioxidants in the human body. To this date, the role of systemic
      antioxidant supplementation in Keratoconus patients has yet to be studied. In addition, it
      has yet to be established as to whether there is a correlation between serum antioxidant
      levels, and the severity of disease in the Keratoconus patient. The investigators propose to
      investigate the plasma levels of antioxidants in relation to disease severity. The
      investigators will also investigate the role of antioxidant supplementation—consisting of
      parenteral Glutathione (GSH), and Vitamins A, C and E—in delaying the disease progression in
      Keratoconus.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Acuity Measured by Snellen Chart</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cornea thickness as measured by video keratography</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Vitamin A</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Blood draws to look at plasma level of Vitamin A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Vitamin C</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Blood draws to look at plasma level of Vitamin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Vitamin E</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Blood draws to look at plasma level of Vitamin E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Glutathione (GSH)</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Blood draws to look at plasma level of GSH</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Placebo with Dietary Sources of Vitamins</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Persons assigned to placebo, who obtain Vitamins A, C, E and Glutathione from dietary sources alone, and have not been on oral RDA supplementation, in the 1 month leading up the time of enrollment and throughout the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Persons assigned to the study medication, and are continuing the take an oral RDA supplementation, in the form of Centrum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidants (Vitamins A,C, E) plus GSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Persons assigned to the study medication alone, without oral RDA supplementation in the 1 month leading up the time of enrollment and throughout the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Centrum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Persons assigned to placebo, who have been on oral RDA supplementation, who would continue to do so throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antioxidants (Vitamins A,C,E) plus GSH</intervention_name>
    <description>Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).</description>
    <arm_group_label>Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum</arm_group_label>
    <arm_group_label>Antioxidants (Vitamins A,C, E) plus GSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill</description>
    <arm_group_label>Placebo with Dietary Sources of Vitamins</arm_group_label>
    <arm_group_label>Placebo plus Centrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Centrum</intervention_name>
    <description>Centrum</description>
    <arm_group_label>Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum</arm_group_label>
    <arm_group_label>Placebo plus Centrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Dietary Sources</intervention_name>
    <description>From dietary sources of vitamins.</description>
    <arm_group_label>Placebo with Dietary Sources of Vitamins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants would be without illness or condition that could make follow-up, or
             compliance with study medication difficult.

          -  Participants may have a prior diagnosis of Keratoconus, or may be diagnosed at the
             initial visit.

          -  Participants should not have an eye diagnosis, other than Keratoconus, that could
             adversely influence the visual acuity.

          -  These participants must not have had prior surgical procedure to treat Keratoconus,
             including collagen cross-linking, Intacs ring segments, or corneal transplantation.

        Exclusion Criteria:

          -  would exclude smokers and former-smokers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Koo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chantey Roberts, B.A.</last_name>
    <phone>561-515-1534</phone>
    <email>c.roberts3@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute-- Palm Beach Gardens</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chantey Roberts, B.A.</last_name>
      <phone>561-515-1534</phone>
      <email>c.roberts3@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Koo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Forster, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Ellen Koo</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Keratoconus progression</keyword>
  <keyword>Vitamins and keratoconus</keyword>
  <keyword>Vitamin supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

